Korro Bio outlines $3.5B market for KRRO-121 at Analyst Day. First-in-class RNA editing therapy targets urea cycle disorders and hepatic encephalopathy.

Korro Bio Unveils $3.5B RNA Editing Play at Analyst Day, Eyes 2026 Clinical Entry

Korro Bio reveals KRRO-121 preclinical data showing 20-25% editing drives ammonia control. Targets $3.5B market with H2 2026 IND filing.

Korro Bio Unveils KRRO-121 Preclinical Data at Analyst Day, Targets $3.5B Ammonia Control Market

Korro Bio unveils KRRO-121 at Analyst Day, targeting $3.5B ammonia control market after 80% stock crash. Regulatory filing expected H2 2026.

Korro Bio Unveils KRRO-121 at Analyst Day: RNA Editing Pivot Targets $3.5B Ammonia Control Market

Korro Bio targets $3.5B ammonia market with KRRO-121 at Analyst Day. RNA editing approach could disrupt Amgen's Ravicti with once-every-2-week dosing.

Leadership at Korro Bio

Executives at Korro Bio

Ram Aiyar

Jeffrey Cerio

Loïc Vincent

Todd Chappell

Board Members at Korro Bio

Ali Behbahani

Jean-François Formela

Katharine Knobil

Nessan Bermingham

Rachel Meyers

Timothy Pearson

Recent News about Korro Bio

Korro Bio Unveils $3.5B RNA Editing Play at Analyst Day, Eyes 2026 Clinical Entry

Korro Bio Unveils KRRO-121 Preclinical Data at Analyst Day, Targets $3.5B Ammonia Control Market

Korro Bio Unveils KRRO-121 at Analyst Day: RNA Editing Pivot Targets $3.5B Ammonia Control Market

Korro Bio Unveils KRRO-121 at Analyst Day, Eyes $3.5 Billion Ammonia Market with First-in-Class RNA Editing Approach